I’m moving forward with my own Eloralintide research and will be placing my order for the vials I require this Sunday, October 4. If anyone wants to participate in the Dark Horse controlled research cycle, I need to know by: SUNDAY, OCTOBER 4 — 12:00 NOON ET The objective here is not simply for everyone to obtain Eloralintide. The objective is to establish a common research window, control as many variables as reasonably possible, track what each participant is doing, and compare our actual observations as a group. If you're interested but still need more information before deciding, I posted a detailed breakdown: “What’s the Difference Between Cagrilintide and Eloralintide?” That post covers: - How the receptor profiles differ - Why Eloralintide’s preferential AMY1 activity interests me - Clinical research and reported side effects - Why I chose Eloralintide rather than Cagrilintide - Why fat loss vs. lean-mass preservation is one of the major things I want to track - Why I want to evaluate Eloralintide standalone rather than immediately stacking it with another metabolic compound Read that first if you're still on the fence. If you want to participate in the DH controlled research cycle, notify me no later than Sunday at 12 noon ET. After that, I’m placing my order and moving forward.

My daughter-in-law and the entire household just tested positive for COVID. Even the Frenchies! Kids are back in school. Summer vacations are over. Everyone is back into the daily grind—and apparently COVID got the memo. Halloween is next. Then Thanksgiving. Then Christmas. Then New Year's. They're all coming fast, and with them come family gatherings, travel, disrupted routines and a whole lot more exposure. So, its got me thinking: What’s your health plan for the next 90 days?

I've been digging deeper into Eloralintide, and based on my own research objectives, I've decided I want to research it specifically for food noise—particularly whether it can quiet that persistent sweet-tooth noise. That got me thinking: rather than doing this completely on my own, is there enough interest to put together a coordinated Dark Horse Eloralintide Research Group? THIS IS NOT A GROUP BUY - The objective isn't simply to purchase product. The objective is to establish a common research window, track what we're doing, and compare actual observations as a community instead of collecting random anecdotes. We are our own research subjects. Each person may have a completely different research objective and may choose a different protocol. What we'll share is a common tracking framework and a defined Dark Horse research window so we can actually compare what we're observing. WHY ELORALINTIDE? Eloralintide is Lilly's investigational selective amylin-receptor agonist. It is not another GLP-1. Lilly has completed a 48-week Phase 2 trial studying Eloralintide as a standalone compound. The fixed weekly doses studied were: 1 mg — 3 mg — 6 mg — 9 mg / There were also dose-escalation groups. At 48 weeks, average weight reduction ranged from approximately 9.5% at 1 mg to 20.1% at 9 mg. The study also included body-composition analysis looking at fat mass versus lean mass—not simply changes on the scale. That's important because it gives us actual human clinical research to start from, rather than somebody's internet protocol. THE DARK HORSE RESEARCH WINDOW As a group, we'll establish either a 12- or 16-week research window. That does not mean everybody has to follow the same protocol or even research Eloralintide for exactly the same amount of time. Your individual research duration should be driven by your objective. You might determine that your objective calls for 10 weeks, 12 weeks, 16 weeks, 24 weeks or something completely different. What I'm looking to standardize is the Dark Horse tracking and reporting window.

What's the Difference Between Cagrilintide and Eloralintide? Cagrilintide and Eloralintide are both long-acting amylin receptor agonists—peptides designed to mimic aspects of the natural hormone amylin to reduce appetite and increase satiety—but they differ significantly in their receptor selectivity and clinical development profiles. Receptor Selectivity Cagrilintide: Acts as a broader, non-selective amylin analogue. It activates multiple receptors across the amylin/calcitonin receptor family, including AMY1, AMY2, AMY3 and the calcitonin receptor. Eloralintide: Acts as a selective amylin receptor agonist developed by Eli Lilly. Rather than broadly activating the receptor family, Eloralintide preferentially targets the AMY1 receptor, with substantially greater activity at AMY1 than at the calcitonin receptor. That distinction—broad receptor activity versus preferential AMY1 activity—is one of the major reasons I find Eloralintide interesting. Clinical Trials and Administration Cagrilintide: Has been evaluated as a monotherapy and is also being developed in combination with other incretin-based therapies, most notably semaglutide as CagriSema. Cagrilintide broadly activates multiple amylin receptor complexes as well as the calcitonin receptor. Eloralintide: Has been evaluated as a once-weekly standalone subcutaneous injection, including a 48-week Phase 2 study that demonstrated substantial, dose-dependent reductions in body weight. Eloralintide is a highly selective amylin receptor agonist engineered by Eli Lilly to preferentially target the human AMY1 receptor rather than broadly activating the entire amylin/calcitonin receptor family. The theory behind that selectivity is particularly interesting: preserve strong amylin-mediated satiety signaling while potentially producing a different tolerability profile than broader amylin receptor activation. Side Effects Both Cagrilintide and Eloralintide influence appetite and satiety signaling, and gastrointestinal effects are prominent adverse events reported with this class.

I've been seeing some version of this more and more: Response begins to decline → increase the dose of the same GLP → response declines again → increase the dose again. Eventually the question becomes: “Why isn't my GLP working anymore?” I recently listened to Alex Kikel discuss this issue, and he raised an interesting theory that I think is worth digging into. Kikel questions whether continually titrating the same GLP agonist upward as response declines is necessarily the answer. We've all seen the pattern: My GLP isn't working like it used to.↓ Increase the dose of the same GLP.↓ Response declines again.↓ Increase the dose again. But what if continually pushing the same agonist through the same receptor pathway isn't the answer? Kikel's hypothesis is that with prolonged and increasingly aggressive GLP agonist exposure, we may eventually be dealing with something beyond simple tolerance or temporary receptor desensitization. He uses the term “receptor decay.” In other words, what if continually pushing the same signaling pathway harder eventually changes the availability or responsiveness of the receptors we're trying to stimulate? Likel bases this theory on his own research and observations of what he has seen with prolonged GLP use. I think his observations raise a legitimate question that is worth taking into the published research and investigating further. SO WHAT DOES HE PROPOSE? Instead of automatically continuing to increase the dose of the same GLP agonist, Kikel discusses changing the agonist and changing the receptor signaling profile. That also fits with something Kikel has consistently advocated: Use the lowest possible dose that produces the desired benefit. The idea isn't: “My GLP stopped working, therefore I need more.” It's questioning whether continuing to push the same agonist at increasingly higher doses makes sense when the response has already begun to decline. Look at the different receptor profiles: Semaglutide → GLP-1 Tirzepatide → GLP-1 + GIP